Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,441 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,441 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01876953 | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid… | Phase 1 / Phase 2 | terminated | Jun 13, 2013 | City of Hope Medical Center | Due to the budget issues, the study discontinued at Phase II. | Funding |
| NCT03759184 | Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte… | Phase 1 | terminated | Nov 29, 2018 | National Cancer Institute (NCI) | The study was closed after \> 1 year of inactivity. | Other (stated, no rule matched) |
| NCT03668392 | Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic…(ALL2518) | Phase 2 | terminated | Sep 12, 2018 | Gruppo Italiano Malattie EMatologiche dell'Adulto | low enrollment rate | Enrollment / accrual |
| NCT04893915 | Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS | Phase 2 | withdrawn | May 20, 2021 | Washington University School of Medicine | No funding support | Funding |
| NCT03151408 | An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults… | Phase 3 | terminated | May 12, 2017 | Helsinn Healthcare SA | The IDMC recommended to stop the study prematurely due to a lack of efficacy. | Efficacy / futility |
| NCT03696537 | IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT | Phase 1 | terminated | Oct 4, 2018 | Naoyuki G. Saito, M.D., Ph.D. | Extreme toxicity | Safety / toxicity |
| NCT04209621 | Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | terminated | Dec 24, 2019 | National Heart, Lung, and Blood Institute (NHLBI) | Due to unexpected sudden death on study. | Other (stated, no rule matched) |
| NCT04961801 | Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation… | Phase 1 / Phase 2 | withdrawn | Jul 14, 2021 | Shin Mineishi | Manufacturer AstraZeneca withdrew the study due to lack of funding | Drug supply |
| NCT04448834 | Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL | Phase 2 | withdrawn | Jun 26, 2020 | Dorothy Sipkins, MD, PhD | Study not moving forward | Other (stated, no rule matched) |
| NCT04331483 | A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults…(EVAADE) | N/A | withdrawn | Apr 2, 2020 | Centre Leon Berard | modification of the intervention before patient's enrollment, new protocol submitted | Enrollment / accrual |
| NCT03922477 | A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in… | Phase 1 | terminated | Apr 22, 2019 | Hoffmann-La Roche | The Sponsor decided to discontinue the development of atezolizumab in combination with magrolimab… | Sponsor / business decision |
| NCT04044560 | Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant(OZM-097) | Phase 2 | terminated | Aug 5, 2019 | University of British Columbia | Slow enrolment, loss of funding | Enrollment / accrual |
| NCT04160195 | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for… | Phase 1 | terminated | Nov 12, 2019 | National Cancer Institute (NCI) | The original principal investigator left the National Institutes of Health (NCI) and the decision… | Investigator |
| NCT03761069 | Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias | Phase 1 | terminated | Dec 3, 2018 | PTC Therapeutics | Sponsor terminated the study. | Other (stated, no rule matched) |
| NCT03851081 | Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed… | Phase 1 / Phase 2 | withdrawn | Feb 22, 2019 | Roswell Park Cancer Institute | no accrual | Enrollment / accrual |
| NCT00792831 | Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed… | Phase 2 | terminated | Nov 18, 2008 | Italfarmaco | Protocol needs complete restructuring in order to make it feasible and to complete the enrollment… | Enrollment / accrual |
| NCT03951961 | Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After… | Phase 2 | terminated | May 16, 2019 | University of Jena | Insufficient Recruitment | Enrollment / accrual |
| NCT04044209 | A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade… | Phase 2 | withdrawn | Aug 5, 2019 | Yale University | No patients were able to be screened nor enrolled. | Enrollment / accrual |
| NCT04097301 | Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | Phase 1 / Phase 2 | terminated | Sep 20, 2019 | AGC Biologics S.p.A. | Inability to close the study in a clinically relevant time frame | Other (stated, no rule matched) |
| NCT00740181 | Decitabine, Cytarabine, GCSF for Refractory AML/MDS | Phase 2 | terminated | Aug 22, 2008 | Brown University | Lack of efficacy | Efficacy / futility |
| NCT02545283 | A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants…(MIRROS) | Phase 3 | terminated | Sep 9, 2015 | Hoffmann-La Roche | The study was stopped for futility based on efficacy results at the interim analysis; no unexpected… | Safety / toxicity |
| NCT03404726 | A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in… | Phase 1 | terminated | Jan 19, 2018 | Bayer | Lack of sufficient clinical benefit | Other (stated, no rule matched) |
| NCT03153514 | Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's…(CLLTX1) | Phase 2 | terminated | May 15, 2017 | German CLL Study Group | Prematurely terminated due to poor accrual | Enrollment / accrual |
| NCT02228382 | Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive… | Phase 4 | terminated | Aug 29, 2014 | Pfizer | not stated | Not stated |
| NCT02608307 | Medical Treatment Decision Making Using Adaptive Conjoint Analysis | — | terminated | Nov 18, 2015 | St. Jude Children's Research Hospital | Slow accrual and COVID-19 restrictions | COVID-19 / pandemic |
| NCT03797261 | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic… | Phase 1 | terminated | Jan 9, 2019 | AbbVie | Safety | Safety / toxicity |
| NCT03557970 | JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | terminated | Jun 15, 2018 | OHSU Knight Cancer Institute | Not enough enrollment to determine efficacy | Efficacy / futility |
| NCT04973618 | Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML | Phase 1 | withdrawn | Jul 22, 2021 | Aptevo Therapeutics | Change of strategy | Sponsor / business decision |
| NCT03519984 | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With… | Phase 1 | terminated | May 9, 2018 | University of Southern California | Study drug supply issue | Drug supply |
| NCT02627677 | A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia(OPTIC-2L) | Phase 3 | terminated | Dec 11, 2015 | Ariad Pharmaceuticals | The study was stopped due to operational feasibility and not due to any safety concerns | Safety / toxicity |
| NCT02910752 | CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell… | Phase 1 / Phase 2 | suspended | Sep 22, 2016 | Shanghai Jiao Tong University School of Medicine | Low enrollment | Enrollment / accrual |
| NCT02795520 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute… | Phase 1 / Phase 2 | terminated | Jun 10, 2016 | OncoTherapy Science, Inc. | slow patient accrual | Enrollment / accrual |
| NCT02078960 | A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given… | Phase 1 / Phase 2 | terminated | Mar 5, 2014 | Teva Branded Pharmaceutical Products R&D, Inc. | Inability to accrue additional sites and enroll an adequate number of subjects. | Enrollment / accrual |
| NCT03639324 | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL(RIVe-CLL/SLL) | Phase 1 | withdrawn | Aug 21, 2018 | Virginia Commonwealth University | Slow Accrual | Enrollment / accrual |
| NCT00210119 | Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in…(AFR22) | Phase 2 | terminated | Sep 21, 2005 | Institut Bergonié | not stated | Not stated |
| NCT03943342 | Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After… | Phase 2 | withdrawn | May 9, 2019 | Kerry Rogers | Study not feasible | Other (stated, no rule matched) |
| NCT01620216 | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic… | Phase 2 | terminated | Jun 15, 2012 | OHSU Knight Cancer Institute | Unable to recruit enough eligible subjects | Enrollment / accrual |
| NCT01246752 | Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional…(AML) | Phase 3 | terminated | Nov 23, 2010 | University Hospital Carl Gustav Carus | decreased recrucial rate as the likelihood of achieving the envisioned patient number in a… | Other (stated, no rule matched) |
| NCT02770820 | Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly… | Phase 1 / Phase 2 | terminated | May 12, 2016 | Fred Hutchinson Cancer Center | Terminated due to funding difficulties | Funding |
| NCT01158885 | Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia | Phase 2 | terminated | Jul 8, 2010 | Therapeutic Advances in Childhood Leukemia Consortium | Study terminated for lack of accrual. | Enrollment / accrual |
| NCT04051996 | GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older… | Phase 2 | terminated | Aug 9, 2019 | Yale University | Unable to accrue patients following COVID-19 study pause. | COVID-19 / pandemic |
| NCT00003405 | Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute… | Phase 2 | withdrawn | May 24, 2004 | Rush University Medical Center | No enrollment | Enrollment / accrual |
| NCT00766779 | HCT Versus CT in Elderly AML | Phase 3 | terminated | Oct 6, 2008 | European Society for Blood and Marrow Transplantation | Recommendation of DMC | Other (stated, no rule matched) |
| NCT02319369 | Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine… | Phase 1 | terminated | Dec 18, 2014 | Daiichi Sankyo | This study was terminated based on a business decision by the Sponsor. | Sponsor / business decision |
| NCT03588936 | Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant | Phase 1 | terminated | Jul 17, 2018 | Medical College of Wisconsin | Poor accrual and loss of funding. | Enrollment / accrual |
| NCT01585688 | Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL | Phase 1 / Phase 2 | terminated | Apr 26, 2012 | Gilead Sciences | Study was terminated due to lack of efficacy, as a result, the stability program for the drug… | Efficacy / futility |
| NCT04464889 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem… | Phase 1 | withdrawn | Jul 9, 2020 | Medigene AG | Medigene transfered all rights to a new Sponsor | Other (stated, no rule matched) |
| NCT02298166 | Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or… | Phase 3 | terminated | Nov 21, 2014 | University of Ulm | The manufacturer Arog Pharmaceuticals Inc has terminated the Agreement Concerning the Support of an… | Drug supply |
| NCT00900120 | Collecting and Storing Blood Samples From Patients With Cancer | — | withdrawn | May 12, 2009 | University of Medicine and Dentistry of New Jersey | Will be replaced by honest broker program | Other (stated, no rule matched) |
| NCT02305563 | An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose… | Phase 1 / Phase 2 | terminated | Dec 2, 2014 | Bristol-Myers Squibb | Business objectives have changed, slow accrual, the standard of care for the patient population… | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 31, 2022source: clinicaltrials